戻る
Passage Bio Inc (PASG) 収入
PASG 株価推移チャート
PASG 収入
Passage Bio Inc
$6.89
-2.88%
$-0.2
終値： Mar 26, 16:00:00 GMT-4
$6.89
0%
$0
アフターマーケット：Mar 26, 20:00:00 GMT-4
主要データ
前終値
$7.09
始値
$7.02
当日レンジ
$6.88 - $7.26
52週レンジ
$5.12 - $20
取引高
9.4K
平均取引高
58.2K
配当利回り
--
1株当たり利益(TTM)
-14.44
時価総額
$22.1M
PASGとは何ですか？
Passage Bio, Inc. operates as a genetic medicines company. The company is headquartered in Philadelphia, Pennsylvania and currently employs 60 full-time employees. The company went IPO on 2020-02-28. Its lead clinical product candidate, PBFT02, seeks to elevate progranulin levels to enhance lysosomal function and slow disease progression across a variety of neurodegenerative diseases. PBFT02 utilizes an adeno-associated virus serotype 1, or AAV1, capsid to deliver a functional granulin gene, encoding progranulin (PGRN), to the brain via intra cisterna magna (ICM) administration. Its development programs consist of PBFT02 for the treatment of FTD-GRN, PBFT02 for the treatment of FTD-C9orf72 and amyotrophic lateral sclerosis, and PBFT02 for the treatment of Alzheimer’s disease. Its clinical product candidates include PBGM01, PBKR03 and PBML04. The company has one unnamed preclinical research program that explores multiple potential treatment targets for Huntington's disease.